Refractory immune thrombocytopenic purpura: current strategies for investigation and management

@article{Psaila2008RefractoryIT,
  title={Refractory immune thrombocytopenic purpura: current strategies for investigation and management},
  author={Bethan Psaila and James B Bussel},
  journal={British Journal of Haematology},
  year={2008},
  volume={143}
}
There is currently no consensus on how best to manage refractory immune thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment due to the wide spectrum of patients' requirements and responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article suggests investigations to identify factors that may exacerbate thrombocytopenia and underlie poor therapeutic responses, and… Expand
Refractory immune thrombocytopenia (ITP) with suspected Evans syndrome requiring quadruple therapy
TLDR
This case of recurrent severe form of ITP is reported, which is not only unique due to the aggressive treatment required, but also because patient also had investigation results suggestive of autoimmune hemolytic anemia raising suspicion of Evans Syndrome. Expand
Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat.
  • J. Bussel
  • Medicine
  • Hematology/oncology clinics of North America
  • 2009
TLDR
Current studies to augment therapy in newly diagnosed ITP patients to prevent chronic disease may lessen the number of patients in chronic disease category. Expand
Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab
TLDR
A 12‐week‐old infant with acute ITP who was unresponsive to intravenous immunoglobulin and corticosteroid, and developed gastrointestinal bleeding is described. Expand
Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemia.
TLDR
A patient with WM developed a refractory, life-threatening and fludarabine-associated thrombocytopenia which could not be explained by the cytotoxic effects of fludARabine. Expand
International consensus report on the investigation and management of primary immune thrombocytopenia.
TLDR
This consensus document aims to report on new data and provide consensus-based recommendations relating to diagnosis and treatment of ITP in adults, in children, and during pregnancy. Expand
Management of Immune Thrombocytopenic Purpura in Children
TLDR
The treatment of immune thrombocytopenic purpura in children is controversial, requiring individualized assessment of the patient and consideration of treatment options, and the traditional and novel treatment options for patients with ITP are considered. Expand
Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports
TLDR
The presented cases have confirmed the potential therapeutic effect of CyA in refractory post‐SE ITP and repeated administration of cyclosporine A which had been ineffective prior to splenectomy. Expand
Immune Thrombocytopenia and Obesity: Predictive Relationship.
TLDR
The cases of 3 children with ITP who failed to achieve remission on different therapeutic approaches including rituximab, vincristine, and romiplostim are presented to propose a possible association between obesity and refractoriness of ITP to different therapeutic approach. Expand
Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines
TLDR
A case of a 26-year-old female with persistent ITP that resolved after the delivery of a CMV-infected infant and placenta is reported and the current ITP guidelines be amended to include assessment for CMV, even in the absence of signs and symptoms, as part of the work-up for severe and refractory ITP, especially prior to undergoing an invasive procedure such as splenectomy. Expand
Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease
TLDR
An updated review of the current clinical and laboratory data is presented, as well as a detailed analysis of the available therapeutic options with their benefits and risks, and also particular associations (pregnancy, relapsed and refractory disease, emergency treatment). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review
TLDR
Patients with chronic immune thrombocytopenic purpura only require treatment if they are bleeding, or prior to scheduled operations, but as spontaneous remission may occur even after 1 year or more, it is justified to defer splenectomy. Expand
Current options for the treatment of idiopathic thrombocytopenic purpura.
TLDR
Treatments for ITP are reviewed with a focus on their mechanism of action and the best available evidence from clinical studies, finding a move towards early aggressive therapy may alter the natural history of this self-perpetuating illness. Expand
Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept
TLDR
Although etanercept appeared to be effective treatment for ITP in these 3 patients, the experimental nature of this treatment and the potential risks must be emphasized. Expand
Splenectomy for immune thrombocytopenic purpura: Surgery for the 21st century
TLDR
It should be a priority for both the hematology and medical community to advocate for clinical trials to rationally study alternatives to splenectomy and laparoscopicSplenectomy should be considered as an additional front line therapeutic option in ITP patients. Expand
Management of patients with refractory immune thrombocytopenic purpura
  • J. George
  • Medicine
  • Journal of thrombosis and haemostasis : JTH
  • 2006
TLDR
New agents for patients with ITP are currently in development that enhance platelet production, rather than diminish platelet destruction, and these agents have been effective in maintaining safe platelet counts in patients with chronic ITP that was refractory to splenectomy and other treatments. Expand
Immune thrombocytopenic purpura in adults
TLDR
Patients with platelet counts less than 30 × 109/l or bleeding have to be treated but management decisions should also be based on lifestyle, age, and other medical conditions that may contribute to the risk of serious bleeding. Expand
How I treat idiopathic thrombocytopenic purpura (ITP).
Our goal is to set forth our opinion of the best approach to managing adults with primary idiopathic (autoimmune) thrombocytopenic purpura (ITP), with emphasis on the word “opinion.” The paucity ofExpand
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
TLDR
The evidence to support the use of rituximab in ITP is uncertain and a systematic review of the literature was performed to evaluate the efficacy and safety of this treatment. Expand
Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP).
TLDR
Combination chemotherapy is a useful approach for patients with ITP refractory to conventional treatments both for acute induction and for long-term maintenance therapy. Expand
Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
TLDR
This study shows that splenectomy is a safe procedure and effective in approximately two thirds of patients with chronic ITP, and further studies are required to establish whether surgery-sparing treatments of Chronic ITP have similar or even superior efficacy, risk and cost ratios compared to splenection. Expand
...
1
2
3
4
5
...